September 19, 2015 : DCMS #260

CLINICAL GEMS — The Best from Diabetes Texts

Practical Diabetes Care, 3rd Ed., Excerpt #32: Lipids Part 2 of 6

DISASTERS AVERTED — Near Miss Case Studies

Can Smaller Forks Help Diabetes Patients?

HOMERUN SLIDES — Great Clinical Presentation Highlights

The Present and Future of Insulin Therapy Part 9

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Keith Campbell, Part 2: Advice for Healthcare Providers

TOP SHARED ARTICLES OF THE MONTH
What A Can of Coca-Cola Really Does To Your Body
Next Generation Google Glucose Monitoring Devices in the Making
Beware: Diabetes Results in Significant Electrolyte Disturbances

September 29, 2015

Reminder – on October 1st, 2015, we will be relaunching DiabetesInControl.com. The refreshed site will feature a clean, new look and feel, with enhanced navigation to make it even easier to find all our great content. We’ve also decided to make some of our most popular content, including our “Tools for Your Practice,” subscriber-exclusive to reward our loyal readers. In order to access this content, you will need to register your subscription email address on the new website. Please look for the link to register in the October 3rd e-newsletter.

We often think of CVD and diabetes in the same breath and yet they are not always related. This week, our Clinical Gem looks at how this mindset became the “law of the land.”

Our Diabetes Disaster Averted looks at why patients often need professional help to get them to use smaller forks and why a good dietitian is better than duct tape when it comes to reducing the amount of food our patients eat.

Also, our Homerun Slides focus on the use of SGLTs to treat type 2 diabetes and be sure to check out our Exclusive Interview with Keith Campbell, PharmD and type 1 patient extraordinaire.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

These subtle differences together may account for some of the increased cardiovascular risk in type 2 diabetes. The level of increased risk is the subject of much academic discussion. In large diabetic populations studied in the past, coronary risks were often found to be approximately doubled compared with non-diabetic groups, and the concept of diabetes as a coronary risk equivalent is almost embedded – type 2 patients who have not yet suffered a coronary event have a similar coronary risk as non- diabetic patients who have already had an event. The therapeutic corollary of this view is that all patients require equally intensive secondary prevention treatment.

Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased…

In this week’s Homerun Slides, we look at SGLT2 Inhibition as a novel treatment strategy for type 2 diabetes.

This week, Associate Medical Editor Joy Pape continues her discussion with R. Keith Campbell, MBA, at the 2015 ADA Sessions in Boston. In this segment, he shares his advice with other healthcare providers in regards to how to help their patients. He advocates for patient education now to mitigate the expensive complications that could happen later.